3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Gynecologic
2
Breast
2
Gastrointestinal
1
Conditions
Ovarian Neoplasms
215
Uterine Cervical Neoplasms
144
Endometrial Neoplasms
111
Fallopian Tube Neoplasms
78
Breast Neoplasms
59
Carcinoma, Non-Small-Cell Lung
43
Colorectal Neoplasms
40
Stomach Neoplasms
35
Melanoma
31
Carcinoma, Renal Cell
29
Prostatic Neoplasms
28
Neoplasms
28
Carcinoma, Ovarian Epithelial
28
Pancreatic Neoplasms
26
Triple Negative Breast Neoplasms
25
Esophageal Neoplasms
25
Neoplasm Metastasis
24
Lung Neoplasms
23
Urinary Bladder Neoplasms
22
Head and Neck Neoplasms
21
Colonic Neoplasms
20
Vulvar Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
19
Carcinoma, Transitional Cell
14
Carcinoma, Hepatocellular
14
Uterine Neoplasms
13
Small Cell Lung Carcinoma
13
Sarcoma
13
Rectal Neoplasms
12
Peritoneal Neoplasms
12
Interventions
rucaparib
1
olaparib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
Gynecologic
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts